Millennium Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Millennium Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,501	Closed	-$8K	–	7753
2022 Q2	$8K	Sell	13,501 -77,208	-85%	-$73.9K	﹤0.01%	6736
2022 Q1	$120K	Sell	90,709 -39,619	-30%	-$64.2K	﹤0.01%	6066
2021 Q4	$340K	Sell	130,328 -169,488	-57%	-$512K	﹤0.01%	5418
2021 Q3	$932K	Buy	299,816 +92,273	+44%	+$308K	﹤0.01%	4766
2021 Q2	$772K	Buy	+207,543	New	+$691K	﹤0.01%	4914
2021 Q1	–	Sell	-55,753	Closed	-$187K	–	6681
2020 Q4	$187K	Buy	55,753 +26,501	+91%	+$94.9K	﹤0.01%	4842
2020 Q3	$103	Sell	29,252 -130,215	-82%	-$525K	﹤0.01%	4214
2020 Q2	$734K	Buy	159,467 +61,025	+62%	+$270K	﹤0.01%	3178
2020 Q1	$326K	Buy	+98,442	New	+$451K	﹤0.01%	3129
2019 Q4	–	Sell	-60,146	Closed	-$250K	–	4769
2019 Q3	$250K	Buy	+60,146	New	+$480K	﹤0.01%	3659
2019 Q2	–	Sell	-121,979	Closed	-$1.16M	–	4632
2019 Q1	$1.16M	Sell	121,979 -11,043	-8%	-$43.7K	﹤0.01%	2774
2018 Q4	$411K	Buy	+133,022	New	+$527K	﹤0.01%	3072

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PTP

Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Millennium Management's PHAS Position: Q3 2022 in Review

Millennium Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 13,501 shares — an estimated $8K sold.

Millennium Management first reported a position in PHAS in Q4 2018 and held it in 12 quarters. The position peaked at $1.16M in Q1 2019. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

Millennium Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 13,501 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $8K.
Millennium Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 12 quarters.
Millennium Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.16M in Q1 2019.
38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.